Counseling about risks of congenital anomalies from prescription opioids

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 94, Issue 8, 2012, Pages 620-625

  Brennan, Matthew C ^a   Rayburn, William F ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac defects; Congenital anomalies; Prescription opioid

Indexed keywords

ACETYLSALICYLIC ACID PLUS BUTALBITAL PLUS CAFFEINE; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; BUTALBITAL PLUS CAFFEINE PLUS PARACETAMOL; CARISOPRODOL; COCODAMOL; CODEINE; CODEINE PHOSPHATE PLUS GUAIFENESIN; FENTANYL; HYCET; HYDROCODONE; HYDROCODONE BITARTRATE PLUS IBUPROFEN; HYDROCODONE BITARTRATE PLUS PARACETAMOL; HYDROMORPHONE; IBUDONE; IBUPROFEN; MAGNACET; METHADONE; MORPHINE; OPIATE; OXYCODONE PLUS PARACETAMOL; PARACETAMOL; PARACETAMOL PLUS PENTAZOCINE; PARACETAMOL PLUS TRAMADOL; PENTAZOCINE; PERCOCET; PETHIDINE; PRESCRIPTION DRUG; PRIMALEV; ROBITUSSIN AC; TYLOX; UNCLASSIFIED DRUG; XOLOX; ZAMICET;

ANALGESIA; ATRIOVENTRICULAR SEPTAL DEFECT; CASE CONTROL STUDY; CLEFT LIP PALATE; COHORT ANALYSIS; COMORBIDITY; CONCEPTION; CONGENITAL HEART MALFORMATION; CONGENITAL HYDROCEPHALUS; CONGENITAL MALFORMATION; DNA SYNTHESIS; DOSE RESPONSE; DRUG EXPOSURE; DRUG MEGADOSE; ECHOGRAPHY; EMBRYO DEVELOPMENT; FEMALE; FETUS RISK; FIRST TRIMESTER PREGNANCY; GASTROSCHISIS; GENETIC COUNSELING; GOLD STANDARD; HEART VENTRICLE SEPTUM DEFECT; HUMAN; HYPOPLASTIC LEFT HEART SYNDROME; INGUINAL HERNIA; MATERNAL SERUM; NEURAL TUBE DEFECT; NONHUMAN; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; POSTPARTUM PAIN; PREGNANCY TEST; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PYLORUS STENOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT MALFORMATION; REVIEW; SECOND TRIMESTER PREGNANCY; SPINA BIFIDA; SPONTANEOUS ABORTION; TERATOGENESIS; THIRD TRIMESTER PREGNANCY; WITHDRAWAL SYNDROME;

ANALGESICS, OPIOID; COUNSELING; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; INFANT, NEWBORN; MATERNAL EXPOSURE; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; PRENATAL DIAGNOSIS; SPINAL DYSRAPHISM;

EID: 84865094872     PISSN: 15420752     EISSN: 15420760     Source Type: Journal    
DOI: 10.1002/bdra.23064     Document Type: Review

References (42)

1. Albright B, de la Torre L, Skipper B, et al. 2011. Changes in methadone maintenance therapy during and after pregnancy. J Subst Abuse Treat 41: 347-353.
2. Arlettaz R, Kashiwagi M, Das-Kundu S, et al. 2005. Methadone maintenance program in pregnancy in a swiss perinatal center (II): Neonatal outcome and social resources. Acta Obstet Gynecol Scand 84: 145-150.
3. Atzei A, Gajewska K, Huggon IC, et al. 2005. Relationship between nuchal translucency thickness and prevalence of major cardiac defects in fetuses with normal karyotype. Ultrasound Obstet Gynecol 26: 154-157.
4. Bracken MB. 1986. Drug use in pregnancy and congenital heart disease in offspring. N Engl J Med 314: 1120.
5. Bracken MB, Holford TR. 1981. Exposure to prescribed drugs in pregnancy and association with congenital malformations. Obstet Gynecol 58: 336-344.
6. Broussard CS, Rasmussen SA, Reefhuis J, et al.; National Birth Defects Prevention Study. 2011. Maternal treatment with opioid analgesics and risk for birth defects. Am J Obstet Gynecol 204: 314.e1-314.11.
7. Cunningham GF, Gant NF, Leveno KJ, et al. 2001. Teratology, drugs, and medications. In: Seils A, Noujaim SR, Davis K, editors. Williams obstetrics, 21st ed. New York: McGraw-Hill. pp. 1005-1038.
8. Eder H, Rupp I, Peternell A, Fischer G. 2001. [Buprenorphine in pregnancy]. Psychiatr Prax 28: 267-269.
9. Fetal Echocardiography Task Force, American Institute of Ultrasound in Medicine Clinical Standards Committee, American College of Obstetricians, Gynecologists, Society for Maternal-Fetal Medicine. 2011. AIUM practice guideline for the performance of fetal echocardiography. J Ultrasound Med 30: 127-136.
10. Fox AW, Diamond ML, Spierings EL, et al. 2005. Migraine during pregnancy: options for therapy. CNS Drugs 19: 465-481.
11. Geber WF, Schramm LC. 1975. Congenital malformations of the central nervous system produced by narcotic analgesics in the hamster. Am J Obstet Gynecol 123: 705-713.
12. Heel RC, Brogden RN, Speight TM, et al. 1979. Buprenorphine: a review of its pharmacological properties and therapeutic efficacy. Drugs 17: 81-110.
13. Heil SH, Jones HE, Arria A, et al. 2011. Unintended pregnancy in opioid-abusing women. J Subst Abuse Treat 40: 199-202.
14. Heinonen OP, Slone D, Shapiro S. 1977. Birth defects and drugs in pregnancy. Littleton, MA: Publishing Sciences Group.
15. Hernandez RK, Werler MM, Romitti P, et al. 2012. Nonsteroidal antiinflammatory drug use among women and the risk of birth defects. Am J Obstet Gynecol 206: 228.e1-e8.
16. Hutchings DE, Zmitrovich AC, Hamowy AS, et al. 1995. Prenatal administration of buprenorphine using the osmotic minipump: a preliminary study of maternal and offspring toxicity and growth in the rat. Neurotoxicol Teratol 17: 419-423.
17. Jernite M, Viville B, Escande B, et al. 1999. [Buprenorphine and pregnancy. Analysis of 24 cases]. Arch Pediatr 6: 1179-1185.
18. Jones HE, Kaltenbach K, Heil SH, et al. 2010. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 363: 2320-2331.
19. Jurand A. 1973. Teratogenic activity of methadone hydrochloride in mouse and chick embryos. J Embryol Exp Morphol 30: 449-458.
20. Katz NP, Adams EH, Benneyan JC, et al. 2007. Foundations of opioid risk management. Clin J Pain 23: 103-118.
21. Lejeune C, Aubisson S, Simmat-Durand L, et al. 2001. [Withdrawal syndromes of newborns of pregnant drug abusers maintained under methadone or high-dose buprenorphine: 246 cases]. Ann Med Interne (Paris) 152: 21-27.
22. Loustauneau A, Auriacombe M, Daulouede JP, Tignol J. 2002. [Is buprenorphine a potential alternative to methadone for treating pregnant drug users? Inventory of clinical data in the literature]. Ann Med Interne (Paris) 153: 2S31-2S36.
23. Markham JK, Emmerson JL, Owen NV, et al. 1971. Teratogenicity studies of methadone HCl in rats and rabbits. Nature 233: 342-343.
24. Nakhai-Pour HR, Broy P, Sheehy O, et al. 2011. Use of nonaspirin nonsteroidal anti-inflammatory drugs during pregnancy and the risk of spontaneous abortion. Can Med Assoc J 183: 1713-1720.
25. Nordeng H, Ystrom E, Einarson A, et al. 2010. Perception of risk regarding the use of medications and other exposures during pregnancy. Eur J Clin Pharmacol 66: 207-214.
26. Ofori B, Oraichi D, Blais L, et al. 2006. Risk of congenital anomalies in pregnant users of non-steroidal anti-inflammatory drugs: a nested cause-control study. Birth Defects Res B Dev Reprod Texicol 77: 268-279.
27. Pole M, Einarson A, Rairaudeau N, et al. 2000. Drug labeling and risk perceptions of teratogenicity: a survey of pregnant Canadian women and their health professionals. J Clin Pharmacol 40: 573-577.
28. Robinson SE, Wallace MJ. 2001. Effect of perinatal buprenorphine exposure on development in the rat. J Pharmacol Exp Ther 298: 797-804.
29. Rothman KJ, Fyler DC, Goldblatt A, et al. 1979. Exogenous hormones and other drug exposures of children with congenital heart disease. Am J Epidemiol 109: 433-439.
30. Sanz E, Gomez-Lopez T, Martinez-Quintas MJ, et al. 2001. Perception of teratogenic risk of common medicines. Eur J Obstet Gynecol Reprod Biol 95: 127-131.
31. Saxen I. 1975. Associations between oral clefts and drugs taken during pregnancy. Int J Epidemiol 4: 37-44.
32. Schindler SD, Eder H, Ortner R, et al. 2003. Neonatal outcome following buprenorphine maintenance during conception and throughout pregnancy. Addiction 98: 103-110.
33. Scialli AR, Ang R, Breitmeyer J, et al. 2010. A review of the literature on the effects of acetaminophen on pregnancy outcome. Reprod Toxicol 30: 495-507.
34. Shaw GM, Todoroff K, Velie EM, Lammer EJ. 1998. Maternal illness, including fever and medication use as risk factors for neural tube defects. Teratology 57: 1-7.
35. Substance Abuse and Mental Health Services Administration. 2011. Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-41, HHS Publication No. (SMA) 11-4658. Rockville, MD: Substance Abuse and Mental Health Services Administration.
36. Werler MM, Mitchell AA, Moore CA, et al. 2009. Is there epidemiologic evidence to support vascular disruption as a pathogenesis of gastroschisis? Am J Med Genet A 149A: 1399-1406.
37. Werler MM, Mitchell AA, Hernandez-Diaz S, Honein MA. 2005. Use of over-the-counter medications during pregnancy. Am J Obstet Gynecol 193: 771-777.
38. Williams J, Price CJ, Sleet RB, et al. 1991. Codeine: developmental toxicity in hamsters and mice. Fundam Appl Toxicol 16: 401-413.
39. You WB, Grobman W, Davis T, et al. 2011. Improving pregnancy drug warnings to promote patient comprehension. Am J Obstet Gynecol 204: 318.e1-318.e5.
40. Zagon IS, Verderame MF, McLaughlin PJ, et al. 2002. The biology of the opioid growth factor receptor (OGFr). Brain Res Rev 38: 351-376.
41. Zagon IS, Wu Y, McLaughlin PJ, et al. 1999. Opioid growth factor and organ development in rat and human embryos. Brain Res 839: 313-322.
42. Zierler S, Rothman KJ. 1985. Congenital heart disease in relation to maternal use of Bendectin and other drugs in early pregnancy. N Engl J Med 313: 347-352.